Welcome to our dedicated page for Atomera SEC filings (Ticker: ATOM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Atomera Incorporated’s (NASDAQ: ATOM) SEC filings, offering a detailed view of how the semiconductor materials and technology licensing company reports its activities as a public issuer. Atomera’s filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe its Mears Silicon Technology™ (MST®), licensing-focused business model and risk profile.
Recent Form 8-K filings reference quarterly financial results and related investor presentations, as well as disclosures about Atomera’s use of its corporate website and LinkedIn account as channels for distributing material information under Regulation FD. These filings confirm that Atomera’s common stock, par value $0.001, trades on the Nasdaq Capital Market under the symbol ATOM, and they furnish press releases that discuss revenue levels, operating expenses, cash balances and non-GAAP metrics such as adjusted EBITDA.
Investors reviewing Atomera’s 10-K and 10-Q filings can examine risk factors, business descriptions and financial statements that elaborate on its status as an early-stage enterprise with minimal engineering services and licensing revenues to date. These reports typically cover topics such as joint development agreements, integration licenses, capital requirements and protection of proprietary MST technology, trade secrets and know-how.
Through this filings page, users can also monitor ongoing disclosure about collaborations and customer engagements, as many material announcements are cross-referenced in 8-Ks. Stock Titan’s tools surface Atomera’s latest submissions from the SEC’s EDGAR system and can pair them with AI-powered summaries that explain the key points in plain language, helping readers quickly understand the implications of lengthy 10-Ks, 10-Qs, 8-Ks and related exhibits, as well as track any future insider transaction reports on Form 4.
Atomera Incorporated reported fourth-quarter and full-year 2025 results, highlighting both technical progress and ongoing losses as it commercializes its semiconductor materials technology. The company achieved a breakthrough demonstrating manufacturability of its MST on Gate-All-Around structures and has a top 20 semiconductor customer running wafers on GaN with MST.
For the fourth quarter of 2025, Atomera posted a net loss of $4.4 million, or $0.14 per share, improving from a $5.6 million loss, or $0.17 per share, in the prior quarter. Full-year 2025 revenue was $65,000, down from $135,000 in 2024, while net loss widened to $20.2 million, or $0.65 per share, versus $18.4 million, or $0.68 per share, a year earlier. Adjusted EBITDA loss increased to $16.1 million from $15.4 million.
Atomera ended 2025 with $19.2 million in cash, cash equivalents and short-term investments, down from $26.8 million a year earlier, and had 32.4 million shares outstanding. Management emphasized strong interest in MST from advanced transistor and power applications and hosted a webinar to discuss the results and its commercialization efforts.
Atomera Incorporated updated its corporate governance framework when its Board of Directors approved and adopted Second Amended and Restated Bylaws on February 5, 2026. These amended bylaws are intended to reflect recent changes in the Delaware General Corporation Law.
The company states that these revisions do not materially change the disclosures previously made about its former bylaws in registration statements, prospectuses, and reports filed with the SEC, except for limited differences not detailed here. The full text of the amended bylaws is provided as Exhibit 3.1 to this report.
Atomera (ATOM) filed its Q3 2025 10‑Q, reporting minimal revenue while continuing to invest in R&D and operations. Revenue was $11,000 for the quarter (vs. $22,000 a year ago) and $15,000 year‑to‑date (vs. $112,000 a year ago). The company posted a net loss of $5.57 million for Q3 and $15.75 million for the nine months ended September 30, 2025, reflecting ongoing development and commercialization efforts.
Cash and cash equivalents were $20.3 million, with $18.1 million of working capital. Operating cash use was $11.6 million year‑to‑date. To support liquidity, Atomera utilized at‑the‑market equity programs, selling about 393,000 shares in Q3 2025 for roughly $2.0 million net proceeds and 742,000 shares year‑to‑date for about $5.2 million. After quarter‑end, it sold an additional 171,000 shares for approximately $836,000 net. Shares outstanding were 31,681,033 as of October 23, 2025.
Management concluded disclosure controls and procedures were not effective as of September 30, 2025 due to a previously identified material weakness, which they believe has been remediated and is undergoing testing.
Atomera Incorporated furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company plans to host an earnings call and distribute an investor presentation.
The press release is provided as Exhibit 99.1 and the investor presentation as Exhibit 99.2. This information is furnished under Item 2.02 and is not deemed filed under the Exchange Act.
Atomera Incorporated filed an 8-K under Regulation FD to remind investors that it uses its corporate website and plans to use its LinkedIn account as channels for distributing material information. The company directs shareholders to its Website at www.atomera.com, which hosts press releases, links to SEC reports, and blog-style updates, and to its LinkedIn page at linkedin.com/company/atomera.
This notice indicates that important updates about Atomera, its industry, and its semiconductor technologies may be posted on these platforms in accordance with Regulation FD.
Form 144 filed for Atomera Incorporated (ATOM) discloses a proposed sale of 4,132 common shares with an aggregate market value of $12,999.69, to be executed approximately on 09/03/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 09/01/2025. The filing lists prior sales by the same individual: 3,601 shares sold on 09/02/2025 for $11,381.34 and 4,196 shares sold on 06/11/2025 for $25,729.03. The filer affirms there is no undisclosed material adverse information and the notice includes the standard Rule 144 representations.
Atomera Incorporated (ATOM) filed a Form 144 notifying an intended sale of 3,601 common shares acquired by vesting of restricted stock on 09/01/2025. The broker listed is Morgan Stanley Smith Barney LLC and the approximate date of sale is 09/02/2025 on NASDAQ. The filing reports an aggregate market value of $11,381.34 for the shares to be sold and states the company has 31,482,756 shares outstanding. The filing also discloses two prior sales by Robert Mears in the past three months: 3,537 shares sold on 06/02/2025 for $21,229.36 and 4,196 shares sold on 06/11/2025 for $25,729.20. The filer affirms no undisclosed material adverse information and notes the securities were granted under an issuer equity compensation plan.
Form 144 filed for Atomera Incorporated (ATOM) reports a proposed sale of 4,437 common shares through Morgan Stanley Smith Barney with an aggregate market value of $14,022.90. The shares were acquired by vesting of restricted stock on 09/01/2025 and were granted under the issuer's equity compensation plan. The filing lists prior sales in June by the same person: 4,359 shares on 06/02/2025 and 51,480 shares on 06/03/2025, with gross proceeds of $26,161.35 and $315,957.92, respectively. The filer represents no undisclosed material adverse information.
Atomera Incorporated (ATOM) Form 144 notifies the SEC of a proposed sale of 9,314 common shares by a named holder through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ, with an aggregate market value of $29,437.09. The shares were acquired by vesting of restricted stock from the issuer on 09/01/2025 and were granted under the issuer's equity compensation plan. The filing also discloses prior sales by the same person within the past three months: 9,153 shares sold on 06/02/2025 for $54,938.07 and 128,002 shares sold on 06/12/2025 for $760,394.85. The filer certifies no undisclosed material adverse information and includes customary Rule 144 and Rule 10b5-1 representations.
Company and period: Atomera Incorporated (ATOM) Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
Key financials: Cash and cash equivalents of $22.0 million and working capital of approximately $20.0 million as of June 30, 2025. Total assets were $24.1 million and total stockholders' equity was $21.3 million. Net loss was $(4.967) million for the three months ended June 30, 2025 and $(10.176) million for the six months ended June 30, 2025. Revenue was minimal: approximately $0 for the three months and $4,000 for the six months. Operating expenses for Q2 were $5.193 million (R&D $3.004M; G&A $2.048M; S&M $0.141M).
Liquidity and corporate actions: Management states available funds are sufficient to fund operations for at least 12 months from issuance date. The company generated net proceeds of approximately $3.2 million from ATM sales during the six-month period and approximately $792,000 in Q2; subsequent to period end it raised ~$2.0 million via the ATM. The company disclosed a previously-identified material weakness in internal control over journal entry review and is implementing enhanced controls.